NEWS: Our Blog

> Our Expansions and Added Resources in 2020

Nov 16, 2020 9:00:00 AM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK

0 Comments

 

How has 2020 treated your company? It has been an odd year to say the least, and we are extremely grateful for the opportunities we have had in our field to work alongside and support companies, such as yours, providing medications to help people live the fullest life possible.

While we have been working with our clients on their exciting projects, we have also been working internally on growing! During the past 12 months we have expanded our footprint and capabilities within our current facility as we continue to build trusted partnerships with you – our clients! We have done this by adding the following:

Space

  • 3,000 square feet of additional office space
  • Three additional laboratories that cover approximately 1,600 square feet
  • OHC 3 – 5 lab facility
  • A BSL3 lab facility will be completed in the fourth quarter of 2020

Equipment

  • Two Agilent 6495 QqQ LC-MS/MS instruments
  • Two Agilent 8900 Triple Quad ICP-MS instruments
  • Validated Agilent Mass Hunter software
  • Two Sciex 6500+ LC-MS/MS instruments
  • New Gyrolab xPlore
  • Upgraded Watson LIMS to version 7.6.1
  • One Agilent Bio-Inert UHPLC

Staff

We have also seen a 15% growth in our staff! We continually look for scientists, lab assistants and techs, IT specialists, software developers, business development/marketing, quality assurance, fellows, and report reviewers for example. We invite you to review our openings on our website and consider joining our role serving the pharmaceutical, biotech, and agrochemical industries, as well as academia.

We look forward to working with you in the months wrapping up 2020 as well as in 2021 with our increased space, resources and staff! Please reach out to us at 610-296-3152 or info@alliancepharmaco.com to discuss how our space, equipment and staff can best meet your drug development and drug metabolism project needs.



Any further questions or need an answer?  Please contact Ryan Klein at rklein@alliancepharmaco.com or 919-801-3146.

Read More

> Making the Most of Your Virtual Conference Experience

Nov 10, 2020 2:00:00 PM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK

0 Comments

 

Remember when we used to meet in person for our conference experiences? We would gather at conference centers and hotel complexes to attend great seminars, to have insightful conversation, to reconnect with old friends and to make new friends. Everything has changed this year as we all continue to adapt to the COVID-19 pandemic. We understand that many of us are sad about what we may miss, but we are thankful for the technology available that allows us to still attend conferences virtually. We know great interactions, education and conversations can still occur even if it has to happen online!

Our latest blog offers tips on how you can make the most of your virtual conference experience. We hope these tips help you as you adapt to our “new normal”. We look forward to seeing and meeting with you during virtual events in the months ahead. Thank you for the trust you put into us with your drug development and drug metabolism projects!

Tips for attending a virtual conference

We are all used to packing our bags, traveling and preparing for our interactions when it comes to attending conferences. COVID-19, however; has changed all of that this year. As many conferences are turning into virtual events, we thought we’d highlight some ways you can get the most out of your virtual conference experience.

  • Prepare mentally for attending the conference. You don't want to just "show up" online. Be prepared with any prep work you would have done prior to an in-person conference. This includes being aware of any potential distractions surrounding you, including your email and phone notifications. It’s tempting to try and multi-task in this circumstance, but do what you can to stay focused on the meeting, just like you would if you attended in person.

  • Be bold. Just as you wouldn't attend an in-person conference and stay in your room the entire time, except for a session or two, you must also be bold in these virtual settings. That means being willing to ask the questions, make the introductions and network. Many virtual conference platforms are offering video chats. Don’t be afraid to ask someone for a face-to-face call.

  • Be active on social media. Social media is a great tool for staying connected and asking questions before, during and after a virtual conference. If you aren't comfortable asking in a live event, use that hashtag to ask your questions on social media channels. Not sure you want your question in public spaces? Follow the social media channels of the conference host, speakers, panelists, sponsors, vendors and attendees, and use those direct message features or find the contact info for that direct email or phone call.

  • Take time to stroll. At a conference, you may pick up a cup of coffee and stroll through the booth areas. Do the same with virtual booth access. Vendors are supporting the virtual meeting through funding and their presence at the meeting. Provide some support for them by visiting the virtual booth and learning about their services in between presentations and during the times dedicated to the virtual exhibit hall.

  • Be patient! Just as you are learning to now navigate a virtual conference, so are all the other attendees, vendors and hosts. There will be times when technology doesn't work right, people forget to mute themselves or even random hiccups occur. Some of it may even feel awkward. Through it all, remember we are all working to adapt in the midst of all the changes COVID-19 has brought this year.

  • Don’t leave early. That last session or final connection may just be the one that makes a difference for you and your company. Make sure to take full advantage of the entire schedule and resist the temptation to head to the couch early.

You can find our conference schedule on our website and our social media channels. Please remember we may not have a table set up around the corner of the conference hall, but we are here to answer any of your questions and welcome your conversation. Visit us at our virtual booth and chat with our team through the virtual conference links at our scheduled events. You are also always welcome to contact us at 610-296-3152 or info@alliancepharmaco.com.

We look forward to seeing you at that next virtual conference!


If you’re going to any upcoming conferences and would like to meet with us, please contact Ryan Klein at rklein@alliancepharmaco.com or 919-801-3146.

Read More

> POSTERS: 12th International ISSX Meeting

Nov 15, 2019 10:30:00 AM / by Ryan Klein posted in Pharmaceuticals, Conferences, DMPK

0 Comments

 


Seven hundred scientists, students, and exhibitors convened at the Oregon Convention Center in Portland, Oregon, USA this past July 28–31 for ISSX2019.

Alliance Pharma is proud to have presented the three posters below.
Click poster images below to download a PDF file.

invitroDDIjpg

 

transporter_jpg

 

expansion_jpg


If you’re going to any upcoming conferences and would like to meet with us, please contact Ryan Klein at rklein@alliancepharmaco.com or 919-801-3146.

Read More

> University of Wisconsin Land O’Lakes DMPK Conference

Sep 6, 2019 10:00:00 AM / by Alliance Pharma posted in Pharmaceuticals, Conferences, DMPK

0 Comments

 


University of Wisconsin Land O’Lakes DMPK ConferenceThe Land O’Lakes conference series is one of the longest running and most revered teaching conferences in the pharmaceutical industry. Over the last two decades, the Land O’Lakes conferences have been developed by the division of pharmacy professional development within the school of pharmacy at the University of Wisconsin-Madison and have an impeccable reputation within the pharmaceutical industry for shedding light on cutting edge topics, bringing in knowledgeable experts and having an intimate setting which lends itself to some fantastic networking opportunities. 

We at Alliance Pharma are pleased to announce that we will be attending the 22nd annual Land O’Lakes conference on Drug Metabolism and Applied Pharmacokinetics on September 9th thru September 12th in Madison, Wisconsin. We are excited and eager to hear from industry leaders on the new advances in drug delivery, action and metabolism. This years’ meeting is titled ‘Found in Translation: Adaptive DMPK Strategies’, and will include topics focused on target mediated drug disposition (TMDD), endogenous biomarkers and more.


Target mediated drug disposition requires that we think outside the box in terms of drug distribution and elimination from the body. TMDD often exhibits nonlinear pharmacokinetics and pharmacodynamics due to the drugs unusually high affinity to a binding site.


Endogenous biomarker research, particularly in the drug transporter area, continues to rapidly evolve. Our biomarker team at Alliance is a highly experienced team with significant expertise in biomarker method development and analysis, yet we are always eager to learn more!


If you’re going to the conference and would like to meet with us, please contact Ryan Klein at rklein@alliancepharmaco.com or 919-801-3146.

Read More

> Comparing Methods for Assessing In-Vitro Protein Binding

May 6, 2019 4:00:00 PM / by Taylor MacArthur and Jessica Lipponen posted in Pharmaceuticals

0 Comments

           The extent of binding to proteins is an important parameter to assess when screening drug candidates during in-vitro ADME studies. Assessing the free fraction of drug available in the biological system is critical to understanding its distribution potential, as it is generally believed that the free fraction drives therapeutic outcomes since it is the free drug (that which is not bound to proteins) that can move to and interact with the sites of action, and high binding to proteins can affect the metabolism and elimination of the drug.

          There are three methods most commonly used to assess protein binding, and it is important to assess their advantages and disadvantages when selecting methods to use for screening studies.

Rapid Equilibrium Dialysis (RED) makes use of a device with two chambers separated by a semipermeable membrane. Spiked matrix is added and over an incubation period, the free drug comes to equilibrium across the membrane while proteins and protein-bound drug cannot move across the membrane; free fraction is calculated by comparing the concentration of drug from the protein and protein-bound drug side to the protein-free, free drug side.

#1#2

Advantages: Most common method (easy cross-comparisons), simple apparatus/setup and high throughput

Disadvantages: Requires long-term stability in the matrix (typical incubation period is 4 hours), nonspecific binding to the device/membrane, volume shifts and protein leakage over the incubation period.

Ultracentrifugation (UC) uses high-speed centrifugation to precipitate proteins and protein-bound drug from a spiked matrix; free fraction is calculated by comparing the concentration of drug in the protein-free supernatant and the intact spiked matrix.#4Advantages: Avoids membrane-related issues (nonspecific binding, leakage across membrane, etc.)

Disadvantages: Usually low-throughput, harder to control pH, temperature (conditions that can significantly affect protein binding), requires longer-term stability in matrix (typical centrifugation time is two hours), the supernatant may not be completely protein-free, leading to an artificially high free fraction observed.

Ultrafiltration (UF) uses a two-chambered device separated by a semipermeable filter. Spiked matrix is loaded into the device and centrifuged at moderate speed, during which time free drug passes through the filter while proteins and protein-bound drug cannot; free fraction is calculated by comparing the concentration of drug in the protein-free filtrate and the intact spiked matrix.

#5Advantages: Suitable for unstable compounds (typical centrifugation time is 30 minutes), quick and technically simple, high throughput/useful to screen many compounds to rank free fraction

Disadvantages: Nonspecific binding to the filter membrane or collection chamber (under-estimation of free fraction), molecular sieving may occur (liquid moves through filter more quickly than the drug, under-estimating free fraction)

Read More

> Three Essential Features of an ELISA That Every BioPharmaceutical Scientist Needs to Understand

Apr 26, 2019 11:00:00 AM / by Nathan Fritzinger posted in Pharmaceuticals, Immunoassay, laboratory

0 Comments

          An enzyme-linked immunosorbent assay (ELISA) is a chemical test to detect the presence of proteins or other molecules. The enzyme-labeled antibody binds to antigens leading to a color change that is used to quantify antigen-antibody interactions. Quantification of these concentrations requires measuring the intensity of the color change, which indicates the concentration of antigen bound to the antibody. ELISA’s include four variants: direct, indirect, sandwich, and competitive, which all have their respective advantages and disadvantages.

u2

Benefits of an ELISA

High Sensitivity: The concentration of both antibody and antigen can be quantified on the nanogram scale. This means that scientists can use a smaller amount of enzyme, which still produces a large scale catalytic reaction.

High Specificity: Antibodies are very specific to their targets due to their spatial configuration and chemical structure. They can easily recognize and bind to antigens similar to how a key unlocks a specific door.

Versatility: Indirect ELISA’s allow for multiple primary antibodies created in one species with the same labeled secondary antibody used for detection. Also, it’s easy to wash off any unbound antibodies by applying a detergent solution to the plate.

Clinically approved ELISA tests for diseases like HIV, Lyme disease, and tuberculosis are proving their efficacy and value to the Pharmaceutical industry.

Read More

> AAPS Poster - #M1430-03-017 - Development of an LC-MS/MS Method for Quantification of Cytarabine in Rat Plasma.

Oct 26, 2018 6:49:06 PM / by Karen Pryor

0 Comments

AAPS Poster - #M1430-03-017 - Development of an LC-MS/MS Method for Quantification of Cytarabine in Rat Plasma - ePoster presentation track: BioanalyticsForum3 - Screen 17 - Date/Time 2018-11-05 2:30

Alliance Pharma is gearing up for the #AAPS PharmSci 360 Conference in DC.  Meet Our Scientist for Poster  #M1430-03-017 - Development of an LC-MS/MS

Method for Quantification of Cytarabine in Rat Plasma. Stop by our booth #610 or schedule a meeting with us at the conference Ryan Klein 919-801-3146 or email rklein@alliancepharmaco.com.

 

It’s a great opportunity to connect with leading #pharmaceutical #scientists from across the globe!Conference Announcement Template - D

Read More

> Building Stronger Collaborative Partnerships with Cutting-Edge Instruments

Oct 23, 2018 4:36:17 PM / by Karen Pryor posted in Pharmaceuticals, Philadelphia, bioanalytical, laboratory, Bioanalysis, Growth, 6545XT, QTOF, AdvanceBio

0 Comments

IMG_5349 (002)

Alliance Pharma is dedicated to bringing comprehensive solutions to our collaborative partnerships.  We understand the importance of efficiency and our team of scientists strive to provide the highest analytical services for your project. 

Our recent purchase of multiple Agilent 6545XT AdvanceBio QTOFs – which is specifically designed with biopharmaceutical characterization in mind - provides high resolution and sensitivity for qualitative and quantitative analyses of biomolecules ranging from peptides to intact monoclonal antibodies. The iterative peptide mapping workflow allows us to dig deep into samples with a wide range of analyte concentrations (i.e. host cell proteins and sequence variants). The Agilent 6545XT AdvanceBio QTOF maximizes our uptime by performing thousands of protein injections without degradation of performance with mass accuracies within 10 ppm for glycosylated intact proteins. 

At Alliance Pharma we believe keeping up with the latest technology helps us to provide the best services for our clients.  The 1290 Infinity II LC system when coupled with the 6545XT, represents the next generation LC for ultrahigh-performance liquid chromatography with superior reliability, offering efficient and reproducible separations of biomolecules for detection by MS or integrated UV and FLD modules. 

By using instruments that complement our scientist’s knowledge and experience we meet analytical objectives, increase productivity, and are cost-effective.  Contact us to see how our recent instrument purchase will help keep your project on track.  Call or email Ryan at 919-801-3146 or  rklein@alliancepharmaco.com for more information.

Read More

> Alliance Pharma New Hire

Oct 9, 2018 10:19:28 AM / by Karen Pryor posted in Pharmaceuticals, Leadership, Philadelphia, bioanalytical, laboratory, Employee engagement, Bioanalysis, Growth, New Hire

0 Comments

 

 

Dr. RyanKleinAlliance Pharma has hired Dr. Ryan Klein as Director of Business Development. Dr. Klein has more than 20 years of experience in the pharmaceutical industry developing both oral and topical dosage forms for a range of indications. Dr. Klein began his career at GlaxoSmithKline, where he was an integral component of their drug discovery organization providing drug metabolism and pharmacokinetic expertise to project teams. He was instrumental in the development and implementation of a number of in vitro and in situ ADME models to assess drug absorption, metabolism, and disposition.

After leaving GSK, Dr. Klein joined Tergus Pharma, a CRO providing topical R&D services to the pharmaceutical industry. At Tergus, Ryan filled various roles including leadership positions as the Head of Research & Development and Head of In Vitro Sciences, as the company grew from five employees to approximately seventy five over a seven year period.

Dr. Klein’s areas of expertise include drug permeability, absorption and metabolism in the gastrointestinal tract, liver and skin, intestinal drug transporters, and the anatomy, physiology, and pharmacology of the skin and GI tract. He also has a strong analytical background with extensive experience developing and validating in vitro release testing methods for semi-solid dosage forms, as well as developing and validating HPLC assay and impurities methods.

Leveraging Dr. Klein’s experience on the client side allows Alliance Pharma to collaborate on a higher level with Sponsors, using his in-depth knowledge and vast experience to align the best team of scientists to support each project.

Ryan earned his bachelor’s degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina, and earned his doctoral degree in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina at Chapel Hill. Ryan has authored & co-authored numerous scientific publications and patents, and serves as a member of several pharmaceutical research focus and discussion groups.

To read more or to connect with Ryan, view his LinkedIn profile https://www.linkedin.com/in/ryanrklein/

Read More

> Alliance Pharma Bioanalytical Team Adds New Instrumentation to Expand Large Molecule Bioanalysis Capability

Sep 21, 2018 4:41:17 PM / by Colin Barry, Ph.D. & Scott Ugrin, Ph.D. posted in Pharmaceuticals, bioanalytical, Large Molecule, Bioanalysis

0 Comments

Colin Barry, Ph.D. & Scott Ugrin, Ph.D.

Alliance Pharma’s bioanalytical team provides comprehensive services for both small and large molecules using a variety of platforms from mass spectrometry to ligand binding assays using an assortment of specialized instrumentation. Our analytical laboratories boast thirteen LC-MS/MS systems from three different manufacturers and include various platforms. Nine systems from AB Sciex are each coupled to Shimadzu UHPLC systems, including two API4000 QTRAP systems, two API4000 triple quad systems, three 5500 triple quad systems, and two 6500 triple quad systems. Each system is designed for high sensitivity quantitative analysis of small molecules generated from either in vitro or in vivo studies and in various matrices.

Alliance Pharma’s small molecule mass-spec based bioanalytical team specializes in:

  • Development, optimization, and transfer of bioanalytical assays
  • Method Validation
  • Sample analysis to support clinical (GLP) and non-clinical studies
  • Plasma, serum, whole blood, and all tissue types
  • Biomarker assay development, validation and sample analysis
  • High throughput screening from in vitro ADME assays
  • Metabolite identification

 

The newest additions to the bioanalytical lab include two Agilent 6545 XT Q-ToF high resolution mass spectrometers coupled to Agilent 1290 Infinity II UHPLC systems with PDA and FL detectors. These new systems add additional capacity to our existing high-resolution accurate-mass (HRAM) systems: 1) a Dionex RSLCnano, 2-D nano/micro/cap UHPLC system coupled to a Q Exactive Plus, and 2) an Orbitrap XL from Thermo Scientific. The newest HRAM systems are ideally suited for analysis of proteins and peptides and will allow generation of highly detailed information for intact proteins and antibodies, confirmation of sequence at the peptide level, and sophisticated analysis of both simple and comprehensive post-translational modifications.

The combination of mass accuracy (> 1 ppm) and high resolution (up to 280,000 at m/z 200) allow for increased specificity and sensitivity in extremely complex matrices. The additional capabilities position Alliance Pharma to continue to expand our large molecule qualitative and quantitative analysis capabilities.

Read More